Maheshwari, Rajesh A.
Co-administration of coenzyme Q10 and HMG-CoA reductase inhibitor attenuates oxidative stress, TGF-β, TNF-α, nitrite content and MPO levels against experimentally-induced diabetic nephropathy in rats - Vol.56(4), Oct-Dec - Bangalore Association of Pharmaceutical Teachers of India (APTI) 2022 - 1091-1098p.
Objectives: Diabetes is a major disease that causes a tremendous economic burden
internationally. To tackle this horrible condition, good therapeutic intervention with
nutraceutical is required. These include diabetic nephropathy, which ranges from chronic
kidney disease to end-stage renal failure. Thus, this study used nutraceutical such
coenzyme Q10 and HMG-CoA reductase inhibitor (rosuvastatin) to see how beneficial
they are in treating diabetic nephropathy. Materials and Methods: The animal experiments
were conducted to induce nephropathy by using streptozotocin-nicotinamide. Animals
were divided into five groups such as control, diabetic control, coenzyme Q10,
rosuvastatin and their combination. The renal function test was conducted by estimating
uric acid, creatinine and urea. Antioxidant parameters were assessed by evaluating MDA,
SOD, GSH and catalase activity in renal tissue. Levels of MPO, TGF-β, TNF-α and nitrite
concentration were measured together with alterations in histopathology in the kidneys
were observed in every treated animal. Results: Diabetic rats were studied for signs of
nephropathy, and the results showed elevated levels of urea, creatinine, uric acid, MPO
activity, TGF-β, TNF-α, nitrite and MDA as well as decreased levels of GSH, SOD and CAT
activity. It was shown that when coenzyme Q10 and rosuvastatin were given combined,
renal function tests improved far more quickly than when the two medications were
given separately. Conclusion: This study found that combination therapy improved renal
function and controlled free radical production, inflammatory mediators, and histological
alterations that lead to kidney injury.
PHARMACEUTICS
Co-administration of coenzyme Q10 and HMG-CoA reductase inhibitor attenuates oxidative stress, TGF-β, TNF-α, nitrite content and MPO levels against experimentally-induced diabetic nephropathy in rats - Vol.56(4), Oct-Dec - Bangalore Association of Pharmaceutical Teachers of India (APTI) 2022 - 1091-1098p.
Objectives: Diabetes is a major disease that causes a tremendous economic burden
internationally. To tackle this horrible condition, good therapeutic intervention with
nutraceutical is required. These include diabetic nephropathy, which ranges from chronic
kidney disease to end-stage renal failure. Thus, this study used nutraceutical such
coenzyme Q10 and HMG-CoA reductase inhibitor (rosuvastatin) to see how beneficial
they are in treating diabetic nephropathy. Materials and Methods: The animal experiments
were conducted to induce nephropathy by using streptozotocin-nicotinamide. Animals
were divided into five groups such as control, diabetic control, coenzyme Q10,
rosuvastatin and their combination. The renal function test was conducted by estimating
uric acid, creatinine and urea. Antioxidant parameters were assessed by evaluating MDA,
SOD, GSH and catalase activity in renal tissue. Levels of MPO, TGF-β, TNF-α and nitrite
concentration were measured together with alterations in histopathology in the kidneys
were observed in every treated animal. Results: Diabetic rats were studied for signs of
nephropathy, and the results showed elevated levels of urea, creatinine, uric acid, MPO
activity, TGF-β, TNF-α, nitrite and MDA as well as decreased levels of GSH, SOD and CAT
activity. It was shown that when coenzyme Q10 and rosuvastatin were given combined,
renal function tests improved far more quickly than when the two medications were
given separately. Conclusion: This study found that combination therapy improved renal
function and controlled free radical production, inflammatory mediators, and histological
alterations that lead to kidney injury.
PHARMACEUTICS